Phibro Animal Health (PAHC) EBITDA Margin: History & Chart

Phibro Animal Health Corporation(PAHC)

Drug Manufacturers - Specialty & Generic · Teaneck, NJ

$36.61-0.58 (-1.56%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Phibro Animal Health Corporation

Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.

Teaneck, NJ

2,605 employees

www.pahc.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Daniel Bendheim

View full financials

PAHC EBITDA Margin Metrics

EBITDA MARGIN

16.46%

EBITDA MARGIN AVG TTM

15.62%

EBITDA MARGIN AVG 3Y

12.37%

EBITDA MARGIN AVG 5Y

12.07%

EBITDA MARGIN AVG 10Y

13.27%

EBITDA MARGIN AVG 15Y

13.26%

EBITDA MARGIN AVG 20Y

13.31%

CURRENT VS TTM AVG

+5.35%

CURRENT VS 3Y AVG

+33.02%

CURRENT VS 5Y AVG

+36.36%

CURRENT VS 10Y AVG

+24.04%

CURRENT VS 15Y AVG

+24.15%

CURRENT VS 20Y AVG

+23.68%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Phibro Animal Health Corporation (PAHC)	$1.48B	16.46%	15.62%	12.37%	12.07%
Rapport Therapeutics, Inc. Common Stock (RAPP)vs ›	$1.49B	N/A	N/A	N/A	N/A
GH Research PLC (GHRS)vs ›	$1.48B	N/A	N/A	N/A	N/A
Eton Pharmaceuticals, Inc. (ETON)vs ›	$1.50B	5.15%	0.72%	-7.50%	-11313.48%
Nutex Health, Inc. (NUTX)vs ›	$1.50B	33.84%	32.51%	-30.03%	-1.40%
Maze Therapeutics, Inc. (MAZE)vs ›	$1.46B	36.35%	36.35%	36.35%	36.35%
Healthcare Services Group, Inc. (HCSG)vs ›	$1.45B	3.56%	3.76%	3.79%	3.46%
Certara, Inc. (CERT)vs ›	$1.44B	18.52%	17.87%	16.34%	15.57%
Innoviva, Inc. (INVA)vs ›	$1.54B	47.98%	50.86%	52.39%	67.36%
Syndax Pharmaceuticals, Inc. (SNDX)vs ›	$1.54B	-158.44%	-796.42%	-796.42%	-1562.06%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Phibro Animal Health Corporation (PAHC)

$1.48B

16.46%

15.62%

12.37%

12.07%

Rapport Therapeutics, Inc. Common Stock (RAPP)vs ›

$1.49B

N/A

GH Research PLC (GHRS)vs ›

$1.48B

N/A

Eton Pharmaceuticals, Inc. (ETON)vs ›

$1.50B

5.15%

0.72%

-7.50%

-11313.48%

Nutex Health, Inc. (NUTX)vs ›

$1.50B

33.84%

32.51%

-30.03%

-1.40%

Maze Therapeutics, Inc. (MAZE)vs ›

$1.46B

36.35%

Healthcare Services Group, Inc. (HCSG)vs ›

$1.45B

3.56%

3.76%

3.79%

3.46%

Certara, Inc. (CERT)vs ›

$1.44B

18.52%

17.87%

16.34%

15.57%

Innoviva, Inc. (INVA)vs ›

$1.54B

47.98%

50.86%

52.39%

67.36%

Syndax Pharmaceuticals, Inc. (SNDX)vs ›

$1.54B

-158.44%

-796.42%

-1562.06%

EBITDA Margin FAQ

What is the EBITDA margin for Phibro Animal Health Corporation (PAHC)?

The EBITDA margin for PAHC stock is 16.46%.

Is Phibro Animal Health Corporation's EBITDA margin high or low?

The EBITDA margin of 16.46% is 36% above its 5-year average of 12.07%, near the high end of its 5-year range (3.52%–18.00%).

What is the TTM average EBITDA margin for Phibro Animal Health Corporation (PAHC)?

The TTM average EBITDA margin for PAHC stock is 15.62%.

What is the 3Y average EBITDA margin for Phibro Animal Health Corporation (PAHC)?

The 3Y average EBITDA margin for PAHC stock is 12.37%.

What is the 5Y average EBITDA margin for Phibro Animal Health Corporation (PAHC)?

The 5Y average EBITDA margin for PAHC stock is 12.07%.

What is the 10Y average EBITDA margin for Phibro Animal Health Corporation (PAHC)?

The 10Y average EBITDA margin for PAHC stock is 13.27%.

What is the 15Y average EBITDA margin for Phibro Animal Health Corporation (PAHC)?

The 15Y average EBITDA margin for PAHC stock is 13.26%.

What is the 20Y average EBITDA margin for Phibro Animal Health Corporation (PAHC)?

The 20Y average EBITDA margin for PAHC stock is 13.31%.

DATE	EBITDA MARGIN
2026-06-30	15.50%
2026-03-31	15.75%
2025-12-31	18.00%
2025-09-30	16.69%
2025-06-30	12.18%
2025-03-31	13.26%
2024-12-31	12.00%
2024-09-30	10.25%
2024-06-30	10.11%
2024-03-31	11.06%
2023-12-31	9.85%
2023-09-30	3.52%
2023-06-30	12.68%
2023-03-31	11.01%
2022-12-31	9.95%
2022-09-30	9.52%
2022-06-30	12.26%
2022-03-31	11.53%
2021-12-31	13.02%
2021-09-30	10.46%
2021-06-30	12.26%
2021-03-31	13.25%
2020-12-31	13.57%
2020-09-30	12.15%
2020-06-30	14.14%
2020-03-31	14.03%
2019-12-31	12.97%
2019-09-30	9.45%
2019-06-30	9.44%
2019-03-31	14.31%
2018-12-31	14.91%
2018-09-30	14.76%
2018-06-30	15.59%
2018-03-31	15.91%
2017-12-31	14.85%
2017-09-30	15.01%
2017-06-30	15.35%
2017-03-31	19.39%
2016-12-31	15.17%
2016-09-30	14.96%
2016-06-30	14.20%
2016-03-31	14.73%
2015-12-31	14.61%
2015-09-30	14.58%
2015-06-30	14.39%
2015-03-31	14.49%
2014-12-31	13.26%
2014-09-30	16.25%
2014-06-30	10.31%
2014-03-31	12.95%
2013-12-31	12.92%
2013-09-30	13.31%
2013-06-30	11.97%
2013-03-31	11.94%
2012-12-31	11.46%
2012-09-30	11.24%
2009-12-31	17.65%
2009-06-30	10.78%
2007-06-30	17.44%
2006-06-30	10.11%
2006-03-31	9.03%
2005-12-31	7.80%
2005-09-30	10.22%
2005-06-30	8.74%
2005-03-31	8.25%
2004-12-31	-0.13%
2004-09-30	10.31%
2004-06-30	4.40%
2004-03-31	11.21%
2003-12-31	35.47%
2003-09-30	10.08%
2003-06-30	10.35%
2003-03-31	9.68%
2002-12-31	12.46%
2002-09-30	11.08%

DATE

EBITDA MARGIN

2026-06-30

15.50%

2026-03-31

15.75%

2025-12-31

18.00%

2025-09-30

16.69%

2025-06-30

12.18%

2025-03-31

13.26%

2024-12-31

12.00%

2024-09-30

10.25%

2024-06-30

10.11%

2024-03-31

11.06%

2023-12-31

9.85%

2023-09-30

3.52%

2023-06-30

12.68%

2023-03-31

11.01%

2022-12-31

9.95%

2022-09-30

9.52%

2022-06-30

12.26%

2022-03-31

11.53%

2021-12-31

13.02%

2021-09-30

10.46%

2021-06-30

12.26%

2021-03-31

13.25%

2020-12-31

13.57%

2020-09-30

12.15%

2020-06-30

14.14%

2020-03-31

14.03%

2019-12-31

12.97%

2019-09-30

9.45%

2019-06-30

9.44%

2019-03-31

14.31%

2018-12-31

14.91%

2018-09-30

14.76%

2018-06-30

15.59%

2018-03-31

15.91%

2017-12-31

14.85%

2017-09-30

15.01%

2017-06-30

15.35%

2017-03-31

19.39%

2016-12-31

15.17%

2016-09-30

14.96%

2016-06-30

14.20%

2016-03-31

14.73%

2015-12-31

14.61%

2015-09-30

14.58%

2015-06-30

14.39%

2015-03-31

14.49%

2014-12-31

13.26%

2014-09-30

16.25%

2014-06-30

10.31%

2014-03-31

12.95%

2013-12-31

12.92%

2013-09-30

13.31%

2013-06-30

11.97%

2013-03-31

11.94%

2012-12-31

11.46%

2012-09-30

11.24%

2009-12-31

17.65%

2009-06-30

10.78%

2007-06-30

17.44%

2006-06-30

10.11%

2006-03-31

9.03%

2005-12-31

7.80%

2005-09-30

10.22%

2005-06-30

8.74%

2005-03-31

8.25%

2004-12-31

-0.13%

2004-09-30

10.31%

2004-06-30

4.40%

2004-03-31

11.21%

2003-12-31

35.47%

2003-09-30

10.08%

2003-06-30

10.35%

2003-03-31

9.68%

2002-12-31

12.46%

2002-09-30

11.08%

EBITDA Margin: 16.46%

PAHC EBITDA Margin

PAHC Average EBITDA Margin Chart

PAHC Current vs Average EBITDA Margin Chart

PAHC EBITDA Margin Metrics

PAHC Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

PAHC EBITDA Margin History

Related Metrics